Fujihara K - Search Results

1

Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.

Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL; N-MOmentum study investigators. Cree BAC, et al. Among authors: fujihara k. Lancet Neurol. 2024 Jun;23(6):588-602. doi: 10.1016/S1474-4422(24)00077-2. Lancet Neurol. 2024. PMID: 38760098 Clinical Trial.

2

Neuromyelitis optica spectrum disorders registry system in Iran: Validity of data sets.

Khodaie F, Mohamadi M, Ebrahimi Y, Sahraian MA, Moghadasi AN, Ayoubi S, Goudarzi H, Paybast S, Kamyari N, Asgari N, Fujihara K, Heidari H, Eskandarieh S. Khodaie F, et al. Among authors: fujihara k. Mult Scler Relat Disord. 2024 May 14;87:105685. doi: 10.1016/j.msard.2024.105685. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 38759423

3

Cross-Sectional and Longitudinal Associations between Forearm Bone Mineral Density and Anthropometry in Adult Japanese Men and Women.

Ishizawa M, Fujihara K, Yachida J, Ikeda I, Sato T, Yamada T, Kobayashi A, Tanaka S, Nakagawa Y, Matsuzaka T, Shimano H, Tashiro M, Kodama S, Kato K, Sone H. Ishizawa M, et al. Among authors: fujihara k. J Bone Metab. 2024 Feb;31(1):21-30. doi: 10.11005/jbm.2024.31.1.21. Epub 2024 Feb 29. J Bone Metab. 2024. PMID: 38485238 Free PMC article.

4

Stochastic models for the onset and disease course of multiple sclerosis.

Akaishi T, Misu T, Takahashi T, Fujihara K, Fujimori J, Nakashima I, Aoki M. Akaishi T, et al. Among authors: fujihara k. Clin Neurol Neurosurg. 2024 Apr;239:108224. doi: 10.1016/j.clineuro.2024.108224. Epub 2024 Mar 2. Clin Neurol Neurosurg. 2024. PMID: 38447482

5

Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.

Nakashima I, Nakahara J, Yasunaga H, Yamashita M, Nishijima N, Satomura A, Nio M, Fujihara K. Nakashima I, et al. Among authors: fujihara k. Mult Scler Relat Disord. 2024 Apr;84:105502. doi: 10.1016/j.msard.2024.105502. Epub 2024 Feb 12. Mult Scler Relat Disord. 2024. PMID: 38401202 Free article.

6

Association between screen time, including that for smartphones, and overweight/obesity among children in Japan: NICE EVIDENCE Study 4.

Ikeda I, Fujihara K, Morikawa Yoshizawa S, Takeda Y, Ishiguro H, Yamada Harada M, Horikawa C, Matsubayashi Y, Yamada T, Ogawa Y, Sone H. Ikeda I, et al. Among authors: fujihara k. Endocr J. 2024 Feb 28;71(2):171-179. doi: 10.1507/endocrj.EJ23-0343. Epub 2024 Jan 11. Endocr J. 2024. PMID: 38199254 Free article.

7

Dynamic changes in patient admission and their disabilities in multiple sclerosis and neuromyelitis optica: A Japanese nationwide administrative data study.

Matsumoto Y, Tarasawa K, Misu T, Namatame C, Takai Y, Kuroda H, Fujihara K, Fushimi K, Fujimori K, Aoki M. Matsumoto Y, et al. Among authors: fujihara k. Mult Scler Relat Disord. 2024 Jan;81:105349. doi: 10.1016/j.msard.2023.105349. Epub 2023 Nov 25. Mult Scler Relat Disord. 2024. PMID: 38043366

8

Impact of a history of cardiovascular disease and physical activity habits on the incidence of functional disability.

Kodera R, Fujihara K, Koyama T, Shiozaki H, Mutsuma Y, Yagyuda N, Hatta M, Tsuruoka K, Takeda Y, Araki A, Sone H. Kodera R, et al. Among authors: fujihara k. Sci Rep. 2023 Nov 27;13(1):20793. doi: 10.1038/s41598-023-47913-z. Sci Rep. 2023. PMID: 38012261 Free PMC article.

9

Usefulness of New Criteria for Metabolic Syndrome Optimized for Prediction of Cardiovascular Diseases in Japanese.

Yamazaki Y, Fujihara K, Sato T, Harada Yamada M, Yaguchi Y, Matsubayashi Y, Yamada T, Kodama S, Kato K, Shimano H, Sone H. Yamazaki Y, et al. Among authors: fujihara k. J Atheroscler Thromb. 2024 Apr 1;31(4):382-395. doi: 10.5551/jat.64380. Epub 2023 Nov 17. J Atheroscler Thromb. 2024. PMID: 37981330 Free PMC article.

10

Lifestyle Intervention With Smartphone App and isCGM for People at High Risk of Type 2 Diabetes: Randomized Trial.

Kitazawa M, Takeda Y, Hatta M, Horikawa C, Sato T, Osawa T, Ishizawa M, Suzuki H, Matsubayashi Y, Fujihara K, Yamada T, Sone H. Kitazawa M, et al. Among authors: fujihara k. J Clin Endocrinol Metab. 2024 Mar 15;109(4):1060-1070. doi: 10.1210/clinem/dgad639. J Clin Endocrinol Metab. 2024. PMID: 37931069 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

584 results

Search Page